Can-Fite Biopharma LTD. (CANF) — 6-K Filings

All 6-K filings from Can-Fite Biopharma LTD.. Browse 50 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (50)

6-K Filing — Apr 23, 2026
Can-Fite BioPharma Files 6-K Report — Mar 30, 2026 Risk: low
Can-Fite BioPharma Ltd. filed a Form 6-K on March 30, 2026, reporting information as a foreign issuer. The filing includes a press release dated March 30, 2026,
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Dec 29, 2025 Risk: low
Can-Fite BioPharma Ltd. filed a Form 6-K on December 29, 2025, to report a press release issued on December 26, 2025. This filing incorporates the press release
6-K Filing — Dec 23, 2025
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Dec 16, 2025 Risk: low
On December 16, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is relevant to several of their existing
6-K Filing — Nov 21, 2025
Can-Fite BioPharma Files 6-K Report — Nov 20, 2025 Risk: low
On November 20, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8
6-K Filing — Nov 18, 2025
6-K Filing — Nov 10, 2025
6-K Filing — Nov 3, 2025
Can-Fite BioPharma to Restructure into New Entity '03 Life Sciences' — Oct 3, 2025 Risk: medium
On October 3, 2025, Can-Fite BioPharma Ltd. announced its intention to incorporate its existing business into a new entity, '03 Life Sciences'. This strategic m
Can-Fite BioPharma Files 6-K, Updates SEC Filings — Sep 15, 2025 Risk: low
On September 15, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is intended to update its Registration
Can-Fite BioPharma Ltd. Files 6-K for June 30, 2025 — Aug 28, 2025 Risk: low
Can-Fite BioPharma Ltd. filed a Form 6-K on August 28, 2025, reporting its financial results for the period ending June 30, 2025. The filing includes financial
Can-Fite BioPharma Pancreatic Cancer Study Hits Enrollment Milestone — Jul 30, 2025 Risk: medium
On July 30, 2025, Can-Fite BioPharma Ltd. announced that its Phase 2a study for pancreatic cancer, utilizing its drug Namodenoson, has achieved over a 50% enrol
Can-Fite BioPharma's Piclidenoson Shows Promise in HS Study — Jul 29, 2025 Risk: medium
On July 28, 2025, Can-Fite BioPharma Ltd. announced that its investigational drug, Piclidenoson, showed positive results in a Phase II study for hidradenitis su
Can-Fite's Piclidenoson Shows Promise for Vascular Dementia — Jul 28, 2025 Risk: medium
On July 28, 2025, Can-Fite BioPharma Ltd. announced a breakthrough study from UCLA demonstrating that its drug, Piclidenoson, shows promise as a treatment for v
Can-Fite BioPharma Shareholders Approve All Six Proposals — Jun 30, 2025 Risk: low
On June 30, 2025, Can-Fite BioPharma Ltd. held its Annual General Meeting of Shareholders where all six proposals presented were approved. These proposals were
Can-Fite BioPharma Annual Meeting Adjourned Due to Lack of Quorum — Jun 23, 2025 Risk: medium
Can-Fite BioPharma Ltd. announced on June 23, 2025, that its Annual General Meeting of Shareholders was adjourned for one week due to a lack of quorum. The meet
Can-Fite BioPharma to Present Pancreatic Cancer Study Update at BIO Convention — Jun 16, 2025 Risk: medium
On June 16, 2025, Can-Fite BioPharma Ltd. announced it will present progress on its Phase IIa pancreatic cancer study at the 2025 BIO International Convention i
Can-Fite BioPharma Files Form 6-K — May 16, 2025 Risk: low
On May 16, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating this report into its existing Registration Statements on Form S-8 and Form F-3. The fil
Can-Fite BioPharma Raises $175M for Liver Cancer & Psoriasis Drugs — May 5, 2025 Risk: medium
On May 5, 2025, Can-Fite BioPharma Ltd. announced it has raised a total of $175 million to date for the development of its drugs Namodenoson and Piclidenoson. T
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Apr 17, 2025 Risk: low
On April 17, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, reporting information for the month of April 2025. This filing incorporates by reference a press re
Can-Fite BioPharma Files 6-K, Incorporates Previous Filings — Apr 15, 2025 Risk: low
On April 14, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K report. This filing incorporates by reference previous registration statements on Form S-8 and Form
Can-Fite BioPharma Establishes New Subsidiary for Drug Development — Mar 24, 2025 Risk: medium
On March 24, 2025, Can-Fite BioPharma Ltd. announced the incorporation of its wholly-owned subsidiary, CFB Therapeutics Ltd., in Israel. This subsidiary will fo
Can-Fite BioPharma Files 6-K Report — Mar 20, 2025 Risk: low
On March 20, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating a press release by reference into its existing SEC registration statements. This fili
Can-Fite BioPharma Ltd. Incorporates Israeli Subsidiary — Mar 19, 2025 Risk: low
On March 19, 2025, Can-Fite BioPharma Ltd. announced the incorporation of its wholly-owned subsidiary, CF Pharma Ltd., in Israel. This move is intended to facil
Can-Fite BioPharma Files Routine 6-K Report — Mar 18, 2025 Risk: low
On March 18, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 an
Can-Fite BioPharma Publishes Namodenoson Liver Cancer Research — Mar 3, 2025 Risk: medium
On March 3, 2025, Can-Fite BioPharma Ltd. announced a press release highlighting the publication of research on Namodenoson for liver cancer treatment. The publ
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Feb 18, 2025 Risk: low
On February 18, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is related to its existing Registration
Can-Fite BioPharma to Present Namodenoson Obesity Data — Feb 5, 2025 Risk: medium
On February 5, 2025, Can-Fite BioPharma Ltd. announced its participation in the BIO CEO & Investor Conference 2025. The company will present data on the anti-ob
Can-Fite BioPharma Secures US Patent for Obesity Drug Namodenoson — Jan 27, 2025 Risk: medium
On January 27, 2025, Can-Fite BioPharma Ltd. announced that the US Patent Office granted them a patent for Namodenoson, specifically for its use as an anti-obes
ASCO Recognizes Can-Fite's Namodenoson Liver Protection — Dec 30, 2024 Risk: medium
On December 30, 2024, Can-Fite BioPharma Ltd. announced that the American Society of Clinical Oncology (ASCO) recognized the liver-protective effects of their a
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Dec 4, 2024 Risk: low
Can-Fite BioPharma Ltd. filed a Form 6-K on December 4, 2024, to report information for the month of December 2024. The filing incorporates by reference a press
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Nov 12, 2024 Risk: low
On November 11, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is related to their ongoing registration
Can-Fite BioPharma's Namodenoson Drug Gets Australian Patent Allowance — Nov 4, 2024 Risk: low
Can-Fite BioPharma Ltd. announced on November 4, 2024, that its anti-obesity drug, Namodenoson, has received a patent allowance in Australia. This development i
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Oct 18, 2024 Risk: low
On October 18, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference the first and third paragraphs of a press release (Exhibit 99.1) into
Can-Fite BioPharma Ltd. Files 6-K, Incorporates Press Release — Oct 9, 2024 Risk: low
On October 9, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release into its existing Registration Statements on Form S-8 a
Can-Fite BioPharma Licenses Piclidenoson, Projects $325M Income — Sep 24, 2024 Risk: medium
On September 24, 2024, Can-Fite BioPharma Ltd. announced that Vetbiolix exercised its option to license Piclidenoson for veterinary osteoarthritis. This agreeme
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Sep 16, 2024 Risk: low
On September 16, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K. This report incorporates by reference certain paragraphs from a press release into their existi
Can-Fite BioPharma Files Form 6-K — Aug 30, 2024 Risk: low
On August 30, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating this report into its existing registration statements on Form S-8 and Form F-3. The
Can-Fite BioPharma Ltd. Files 6-K for June 30, 2024 — Aug 29, 2024 Risk: low
Can-Fite BioPharma Ltd. filed a Form 6-K on August 29, 2024, reporting its financial results for the period ending June 30, 2024. The filing includes financial
Can-Fite BioPharma Files 6-K, Incorporates Inducement Letter — Aug 12, 2024 Risk: medium
On August 8, 2024, Can-Fite BioPharma Ltd. entered into an inducement letter with an investor. This letter is incorporated by reference into several of the Comp
Can-Fite BioPharma Raises $10.5M in Public Offering — Aug 9, 2024 Risk: medium
On August 8, 2024, Can-Fite BioPharma Ltd. announced the closing of its previously disclosed underwritten public offering, raising gross proceeds of approximate
Can-Fite BioPharma Updates Namodenoson Patent Status — Jul 29, 2024 Risk: medium
On July 29, 2024, Can-Fite BioPharma Ltd. issued a press release providing an update on its Namodenoson patent. The company is seeking to extend the patent prot
Can-Fite BioPharma Files 6-K, Incorporates Press Release — Jul 11, 2024 Risk: low
Can-Fite BioPharma Ltd. filed a Form 6-K on July 11, 2024, to incorporate by reference a press release into its existing Registration Statements on Form S-8 and
Can-Fite BioPharma Holds Annual Shareholder Meeting — Jul 3, 2024 Risk: low
On July 3, 2024, Can-Fite BioPharma Ltd. filed a Form 6-K to incorporate by reference into its existing registration statements. This filing relates to the comp
Can-Fite BioPharma Reports Namodenoson Success in Liver Cirrhosis — Jul 1, 2024 Risk: medium
On July 1, 2024, Can-Fite BioPharma Ltd. announced positive results from a patient treated with Namodenoson for decompensated liver cirrhosis. The press release
Can-Fite BioPharma: Osteoarthritis Study in Dogs Shows Positive Results — Jun 28, 2024 Risk: medium
On June 28, 2024, Can-Fite BioPharma Ltd. announced positive results from a clinical study in dogs for osteoarthritis, conducted by its partner Vetbiolix. The s
Can-Fite BioPharma Annual Meeting Adjourned Due to Lack of Quorum — Jun 26, 2024 Risk: medium
Can-Fite BioPharma Ltd. announced that its Annual General Meeting of Shareholders, originally scheduled for June 26, 2024, was adjourned due to a lack of quorum
Can-Fite BioPharma: Namodenoson Shows Liver Cancer & Protective Effects — Jun 24, 2024 Risk: medium
On June 24, 2024, Can-Fite BioPharma Ltd. announced breakthrough findings demonstrating Namodenoson's anti-cancer and protective effects in the liver. The press

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX